GlobeImmune, Inc. Offers IPO Details
9/6/2012 8:26:34 AM
More...
|
GlobeImmune, Inc. Files Paperwork for $69 Million IPO
7/3/2012 6:21:39 AM
More...
|
GlobeImmune, Inc.'s GI-4000 in Combination With Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial With Ras Mutation Positive Pancreas Cancer
6/27/2012 9:09:15 AM
More...
|
GlobeImmune, Inc. Initiates Phase 1 Clinical Trial of GI-6301 in Brachyury Expressing Cancers
2/8/2012 11:43:28 AM
More...
|
Gilead Sciences Ltd. (GILD) and GlobeImmune, Inc. Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection
10/25/2011 9:07:48 AM
More...
|
GlobeImmune, Inc. Promotes Jeffrey Dekker to Vice President of Finance
8/31/2011 8:47:43 AM
More...
|
GlobeImmune, Inc. Receives Three Grants Under Federal Therapeutic Discovery Project Program
11/3/2010 8:56:37 AM
More...
|
Phase 2b Study Demonstrates GlobeImmune, Inc.'s GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who Previously Failed Therapy With Standard of Care
11/1/2010 9:27:51 AM
More...
|
GlobeImmune, Inc. Expands GI-5005-02 Phase 2b Trial to Include Additional Treatment Naive IL28B T/T Subjects With Chronic Genotype 1 HCV
10/28/2010 11:01:35 AM
More...
|
GlobeImmune, Inc. Announces Late-Breaker Oral Presentation of GI-5005 Prior Non-Responder Data at AASLD 2010 Meeting
10/1/2010 9:06:22 AM
More...
|
|